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Abstract
Background: Doxorubicin is one of the few chemotherapeutic drugs able to exert both cytotoxic
and pro-immunogenic effects against cancer cells. Following the drug administration, the
intracellular protein calreticulin is translocated with an unknown mechanism onto the plasma
membrane, where it triggers the phagocytosis of tumour cells by dendritic cells. Moreover
doxorubicin up-regulates the inducible nitric oxide (NO) synthase (iNOS) gene in cancer cells,
leading to huge amounts of NO, which in turn acts as a mediator of the drug toxicity and as a
chemosensitizer agent in colon cancer. Indeed by nitrating tyrosine on the multidrug resistance
related protein 3, NO decreases the doxorubicin efflux from tumour cells and enhances the drug
toxicity. It is not clear if NO, beside playing a role in chemosensitivity, may also play a role in
doxorubicin pro-immunogenic effects. To clarify this issue, we compared the doxorubicin-sensitive
human colon cancer HT29 cells with the drug-resistant HT29-dx cells and the HT29 cells silenced
for iNOS (HT29 iNOS-).
Results: In both HT29-dx and HT29 iNOS- cells, doxorubicin did not induce NO synthesis, had a
lower intracellular accumulation and a lower toxicity. Moreover the drug failed to promote the
translocation of calreticulin and the phagocytosis of HT29-dx and HT29 iNOS-cells, which resulted
both chemoresistant and immunoresistant. However, if NO levels were exogenously increased by
sodium nitroprusside, the chemosensitivity to doxorubicin was restored in HT29 iNOS-cells. In
parallel the NO donor per se was sufficient to induce the exposure of calreticulin and to increase
the phagocytosis of HT29 iNOS- cells by DCs and their functional maturation, thus mimicking the
pro-immunogenic effects exerted by doxorubicin in the parental drug-sensitive HT29 cells.
Conclusion:  Our data suggest that chemo- and immuno-resistance to anthracyclines are
associated in colon cancer cells and rely on a common mechanism, that is the inability of
doxorubicin to induce iNOS. Therefore NO donors might represent a promising strategy to
restore both chemosensitivity and immunosensitivity to doxorubicin in resistant cells.
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Background
Despite the improvement in survival, many advanced
solid cancers still remain difficult to treat. Chemotherapy,
which has high success rates in certain tumours, may not
succeed in removing all the cancer cells of solid tumours
when these cells are affected by multidrug resistance
(MDR), a multiple cross-resistance towards different anti-
cancer drugs [1]. Several mechanisms account for the
MDR phenotype, such as the reduced uptake or the
increased efflux of the drug, the genetic modification of
the drug's specific targets, the increased ability to repair
DNA damage or to inactivate the drug through detoxifica-
tion [2]. Several efflux pumps, e.g. the P-glycoprotein
(Pgp) and the MDR-related proteins (MRPs), are often
over-expressed on the membrane of MDR cells and medi-
ate the efflux of a great variety of anticancer agents, such
as anthracyclines, Vinca alkaloids, epipodophyllotoxins,
taxanes, actinomycin-D and mitoxantrone, leading to a
poor prognosis [1].
Chemotherapy usually induces the cancer cells to die in
an apoptotic way, which is poorly immunogenic. How-
ever anthracyclines, in particular doxorubicin, have been
found to be the only chemotherapeutic agents which elicit
also an immunogenic death in tumour cells. Before induc-
ing the apoptosis of tumour cells, doxorubicin has been
shown to induce the translocation of calreticulin (CRT), a
calcium sensor protein which resides in the endoplasmic
reticulum (ER), to the plasma membrane [3]. After such
an exposure, CRT may trigger the recognition and the
phagocytosis of dying cancer cells by dendritic cells (DCs)
[3,4]. CRT was found to be only exposed on cells that suc-
cumb to immunogenic cell death but was lacking on the
surface of cells which undergo a non-immunogenic cell
death. Therefore this protein has been considered deter-
minant for an immuno-mediated cell death [3,4]. Inter-
estingly, recombinant CRT has been successfully used as
an anti-tumour vaccination in immunocompetent mice
when injected with cancer cells treated ex vivo with anthra-
cyclines [4].
Besides inducing CRT translocation to the membrane,
doxorubicin was also found to be the only chemothera-
peutic agent that induces the production of nitric oxide
(NO) [5]. NO is a small signalling molecule synthesized
by three NO synthases (NOS; EC 1.14.13.39) isoforms,
two of which (neuronal NOS/nNOS or NOS I; endothe-
lial NOS/eNOS or NOS III) are mainly constitutive. The
third NOS isoform (NOS II or inducible NOS, iNOS) is
virtually absent in resting cells but is up-regulated by sev-
eral stimuli, like cytokines and bacterial lipopolysaccha-
ride [6]. Doxorubicin itself is a strong iNOS inducer [7,8],
by favouring the degradation of the IkBα inhibitory com-
plex and allowing the NF-κB factor to translocate into the
nucleus and activate the transcription of iNOS gene [9].
NO plays an important role in cell growth, differentiation
and apoptosis [6] and it has been suggested that at least
part of the doxorubicin cytotoxic effect is due to the
increased NO synthesis elicited by the drug [7].
Our group reported earlier that doxorubicin induces NF-
κB activation and NO synthesis in human colon cancer
HT29 cells, but fails to augment the levels of NO in the
drug-resistant HT29-dx sub-clone, where the drug is
pumped out of the cell before it can elicit any nuclear
translocation of NF-kB and increase of iNOS expression
[5,9]. Moreover NO itself was found to modulate the
activity of Pgp and MRP3 transporters, for which doxoru-
bicin is a substrate [1]: indeed NO lowers the Vmax of
doxorubicin efflux by nitrating the MRP3 transporter in
human colon cancer HT29 cells [5,9]. Also in drug-resist-
ant cells, if NO levels are increased by iNOS  inducers
other than doxorubicin or by NO donors, Pgp and MRP3
proteins are inhibited and the doxorubicin accumulation
and toxicity are increased, resulting in a reversion of the
MDR phenotype [5,9-11].
Notably, NO may also regulate the translocation of pro-
teins from ER to the plasma membrane: for example it has
been found to induce the exposure of glucose-transporter
4 onto the plasma membrane [12]. Like CRT, most glu-
cose-transporter 4 molecules reside within the intracellu-
lar vesicular compartment until they are stimulated by
insulin and NO to translocate on cell surface [12].
Since doxorubicin is the only anticancer agent which
induces both NO synthesis and calreticulin translocation,
we hypothesized that NO may be the agent by which dox-
orubicin induces the exposure of CRT, thus acting as an
intracellular mediator of the doxorubicin pro-immuno-
genic effects. Moreover we raised the question whether
chemoresistance and immunoresistance would be associ-
ated in cancer cells: since in chemo-resistant cells doxoru-
bicin fails to induce NO synthesis and cytotoxic effects, we
wondered whether the drug also fails to induce calreticu-
lin translocation in MDR cells and whether this failure
may be due to the lack of NO increase. To this purpose, we
knocked down iNOS  gene by small interfering RNA
(siRNA) in human colon doxorubicin-sensitive HT29
cells and we evaluated the doxorubicin toxic and pro-
immunogenic effects in drug-sensitive HT29 cells, drug-
resistant HT29-dx cells and doxorubicin-sensitive HT29
cells subjected to iNOS silencing (termed "HT29 iNOS-
cells"). Finally we assessed whether the restoration of NO
levels alone was sufficient to rescue the doxorubicin cyto-
toxicity and the immunogenic death in HT29 iNOS- cells.
Results
Doxorubicin fails to induce NO synthesis in HT29-dx and 
HT29 iNOS- cells
After silencing the iNOS gene by small RNA interference
in HT29 cells, as reported under the Methods section, weMolecular Cancer 2009, 8:108 http://www.molecular-cancer.com/content/8/1/108
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checked the expression of the three NOS isoforms in the
wild-type HT29 cells, in the drug-resistant HT29-dx cells
and in the HT29 iNOS- cells. In untreated cells, iNOS pro-
tein was absent in the three cell lines, but was greatly
increased by doxorubicin in HT29 cells. On the opposite
the drug failed to induce iNOS expression in HT29-dx and
HT29 iNOS- cells (Fig. 1A). Real Time-PCR experiments
confirmed these results, showing that doxorubicin signif-
icantly augmented the mRNA transcript of iNOS only in
HT29 cells (Fig. 1B). iNOS mRNA was even lower in con-
trol HT29-dx and HT29 iNOS- cells compared to HT29
cells (Fig. 1B). As far as the other NOS isoforms are con-
cerned, HT29 and HT29-dx showed an equally low basal
expression of eNOS and nNOS proteins, whereas HT29
iNOS- displayed an overexpression of both eNOS and
nNOS (Fig. 1A). Doxorubicin did not change the amount
of eNOS and nNOS in all the cell lines. To assess that our
gene silencing procedure was devoid of any unspecific tar-
geting, we transfected HT29 cells with a scrambled non-
targeting shRNA and we measured the expression of iNOS
protein in the absence and presence of doxorubicin: as
shown in Figure 1C, doxorubicin was still able to induce
iNOS in cells transfected with the scrambled sequence, as
it did in non-silenced HT29 cells.
As a further confirmation of iNOS knockdown efficacy we
measured the NOS activity in the cell lysate and the accu-
mulation of nitrite, the stable derivative of NO, in the
extracellular medium, taken as an index of the actual pro-
duction of NO by the whole cultured cells. Both NOS
activity and nitrite amount were significantly increased in
HT29 cells incubated with doxorubicin, but not in HT29-
dx nor in HT29 iNOS- cells (Fig. 2). NOS activity was also
lower under basal conditions in HT29-dx and HT29 iNOS-
cells compared to HT29 cells, although nitrite production
showed no difference (Fig. 2).
HT29 iNOS- cells are as resistant to doxorubicin 
accumulation and toxicity as HT29-dx cells
After incubation with doxorubicin HT29-dx and HT29
iNOS- cells showed respectively a 75% and 69% lower
intracellular accumulation of the drug in comparison to
iNOS silencing in HT29 cells Figure 1
iNOS silencing in HT29 cells. (A) Western blot detection of iNOS, eNOS, nNOS and GAPDH in HT29, HT29-dx and 
HT29 iNOS- cells. The silencing of iNOS was performed in HT29 cells as reported under the Methods section; then, after a 24 h 
incubation in the absence (-) or in the presence (+) of 5 μmol/L doxorubicin, cells were lysed and Western blotting was per-
formed as described. The expression of the housekeeping protein GAPDH was measured as equal control loading. The results 
shown here are representative of three similar experiments. (B). Real Time-PCR for iNOS in HT29, HT29-dx and HT29 iNOS- 
cells. After a 24 h incubation in the absence (CTRL) or in the presence of 5 μmol/L doxorubicin (doxo), cells were lysed and Real 
Time-PCR was performed as described in the Methods section. Data are represented as mean ± SE (n = 3). Vs HT29 CTRL: * 
p < 0.01; ** p < 0.005. Vs HT29 doxo: ° p < 0.02. (C) HT29 cells were transfected with a non-targeting scrambled shRNA 
sequence (nt shRNA), then incubated in the absence (-) or in the presence (+) of 5 μmol/L doxorubicin for 24 h and subjected 
to Western blot for iNOS and GAPDH.
(140 kDa)
(130 kDa)
(155 kDa)
iNOS
nNOS
eNOS
GAPDH
(37 kDa)
-
-
-
-
doxo -+     -+      -+
HT29
HT29
-dx
HT29
iNOS-
iNOS
(130 kDa)
GAPDH
(37 kDa)
-
-
doxo -+
HT29
nt shRNA
CTRL doxo CTRL doxo CTRL doxo
0
1
2
3
4
i
N
O
S
 
m
R
N
A
 
(
r
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
)
HT29-dx HT29 iNOS- HT29
*
** * *
° °
**
A
B
CMolecular Cancer 2009, 8:108 http://www.molecular-cancer.com/content/8/1/108
Page 4 of 18
(page number not for citation purposes)
HT29 cells (Fig. 3A). The extracellular LDH activity, meas-
ured as an index of the drug cytotoxicity, was significantly
augmented in HT29 cells treated with doxorubicin, while
it did not significantly change in HT29-dx and HT29
iNOS- cells (Fig. 3B).
NO has previously shown to modulate the doxorubicin
accumulation by nitrating the MRP3 protein [5], slowing
down the efflux of the drug and making cells more sensi-
tive to the doxorubicin cytotoxic effects. Therefore, as a
possible explanation for the differences in drug accumula-
tion and toxicity, we checked the presence of nitrated tyro-
sine residues on the MRP3 protein in our cell lines.
Doxorubicin induced a tyrosine nitration of MRP3 in
HT29 cells (Fig. 3C), the only cell line where it evoked a
significant synthesis of NO (Fig. 2). On the other hand,
the drug failed to promote nitration of MRP3 in both
HT29-dx and HT29 iNOS- cells (Fig 3C), where NO levels
remained low (Fig 2). As far as the total level of MRP3 is
concerned, the transporter was present in HT29 and HT29
iNOS-cells at similar amounts, was over-expressed in
HT29-dx cells and was unaffected by the presence of dox-
orubicin in all the three cell lines (Fig. 3C). A similar pat-
tern of expression was observed for Pgp, another
transporter involved in doxorubicin efflux, but in our
experimental conditions no nitrotyrosine residues were
detectable on this protein (Fig. 3C).
To exclude that the reversion of doxorubicin resistance
due to the nitration of MRP3 was a phenomenon limited
to colon cancer, we analyzed other doxorubicin-sensitive
and doxorubicin-resistant cell lines, as well as primary
tumours samples (Figure 4). Similarly to HT29 model,
Pgp and MRP3 were present in the human doxorubicin-
sensitive lung cancer A549 cells and increased in the dox-
orubicin-resistant A549-dx cells (Fig. 4A). The NO donor
sodium nitroprusside (SNP) exerted a nitration of MRP3
in both A549 and A549-dx cells (Fig 4A) and increased the
intracellular drug accumulation in both cell populations
(Fig 4D). On the other hand, doxorubicin was able to
nitrate MRP3 only in sensitive cells, where its intracellular
content was significantly higher than in resistant cells. No
nitration on Pgp was detected (Fig. 4A). In the chronic
myelogenous cell line K562, the total amount of Pgp and
MRP3 was low, whereas both transporters increased in
doxorubicin-resistant K562-dx cells (Fig. 4B). However,
differently from colon and lung cancer, both Pgp and
MRP3 were nitrated by SNP in K562 and K562-dx cells.
Again doxorubicin elicited a tyrosine nitration of these
transporters only in the drug-sensitive cell line (Fig 4B).
The intracellular doxorubicin accumulation was higher in
K562 cells in comparison with A549 or HT29 cells, sug-
gesting a lower activity of Pgp and MRP3 in leukaemia
cells. Moreover the increase of doxorubicin content elic-
ited by SNP was more pronounced in K562 cells, probably
because of the nitration of both Pgp and MRP3 in these
cells (Fig 4D). We also examined three primary tumours
samples: MM98 and OC98 malignant mesothelioma
cells, and HP06 metastatic breast cancer cells. All samples
expressed Pgp and MRP3, and basally accumulated very
Nitrite levels and NOS activity in HT29, HT29-dx and HT29 iNOS- cells Figure 2
Nitrite levels and NOS activity in HT29, HT29-dx and HT29 iNOS- cells. After a 24 h incubation in the absence 
(CTRL) or in the presence of 5 μmol/L doxorubicin (doxo), NOS activity was measured in cell lysates, and extracellular medium 
was checked for nitrite concentration (see Methods section). Measurements were done in duplicate and data are represented 
as mean ± SE (n = 4). Versus HT29 CTRL: * p < 0.01; ** p < 0.02; versus HT29 doxo: ° p < 0.02.
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Intracellular accumulation and cytotoxicity of doxorubicin in HT29, HT29-dx and HT29 iNOS- cells Figure 3
Intracellular accumulation and cytotoxicity of doxorubicin in HT29, HT29-dx and HT29 iNOS- cells. (A) Cells 
were grown in RPMI containing 5 μmol/L doxorubicin for 24 h, then the drug accumulation was measured as described in the 
Methods section. Measurements were done in duplicate and data are represented as mean ± SE (n = 3). Versus HT29 CTRL: * 
p < 0.02. (B) After an incubation of 24 h in the absence (CTRL) or in the presence of 5 μmol/L doxorubicin (doxo), LDH activity 
was measured in the extracellular medium, as reported under the Methods section. Measurements were done in triplicate and 
data are represented as mean ± SE (n = 4). Versus HT29: * p < 0.05. (C) Western blot detection of nitrated MRP3, total MRP3, 
nitrated Pgp, total Pgp and GAPDH. HT29, HT29-dx and HT29-iNOS- cells were incubated for 24 h in the absence (-) or in the 
presence (+) of 5 μmol/L doxorubicin, then cellular lysates were immunoprecipitated with an anti-nitrotyrosine polyclonal anti-
body. Western blotting for MRP3 and Pgp was performed on the immunoprecipitated proteins (see Methods for details). 
Under the same experimental conditions, an aliquot of cells was lysed and directly probed with an anti-Pgp or an anti-MRP3 
antibody to detect total MRP3 or Pgp. The expression of the housekeeping protein GAPDH was measured as equal control 
loading. The results shown here are representative of two similar experiments.
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low amounts of doxorubicin, suggesting that they were
constitutively resistant to doxorubicin (Fig 4C and 4D). As
expected, doxorubicin failed to nitrate Pgp or MRP3; how-
ever also in these models the NO donor SNP induced a
tyrosine nitration of the ABC-transporters (respectively
Pgp in MM98 and OC99 cells, MRP3 in HP06 cells; Fig
4C) and increased the intracellular doxorubicin accumu-
lation (Fig 4D).
iNOS activity is necessary to mediate the pro-
immunogenic effects of doxorubicin
Flow cytometry analysis showed that the fraction of
tumour cells with externalized CRT was low in all the cell
lines (Fig. 5A, 5B) and was significantly increased after
doxorubicin treatment in the HT29 cells (Fig. 5A, 5B). On
the contrary, the CRT exposure on the membrane of
HT29-dx and HT29 iNOS- cells was not changed by doxo-
rubicin. The results obtained in the biotinylation assays,
which examined only the CRT fraction present on the cell
surface, confirmed the flow cytometry results (Fig. 5C).
The amount of CRT in the total cell lysate was similar in
all the three cell lines and was not affected by doxorubicin
(Fig. 5C).
The rate of tumour cells phagocytosis was positively corre-
lated with the levels of exposed calreticulin in that it was
increased by doxorubicin in HT29 cells, but not in HT29-
dx and HT29 iNOS-cells (Fig. 6A, 6B). Functional matura-
tion of DCs followed the same pattern, with increased
alloantigen presentation by DC that had phagocyted dox-
orubicin-treated HT29 (Fig 6C). It is noteworthy in this
context that doxorubicin-treatment overcame the inhibi-
tion induced on DC exposed to the untreated tumour. On
the contrary, experimental conditions that failed to
increase the tumour cells uptake (Fig. 6A, 6B) did not
reverse this inhibition. No activation was observed in
lymphocytes cultured with HT29, HT29-dx or HT29
iNOS- tumour cells in the absence of DCs (not shown).
The chemoresistance towards doxorubicin is reversed by 
increasing the NO levels in HT29 iNOS- cells
To provide a further confirmation of the correlation
between NO levels and chemoresistance to doxorubicin,
we modulated the level of NO in HT29 iNOS- cells by add-
ing the NO-donor SNP and by removing NO with 2-phe-
nyl-4,4,5,5,-tetramethylimidazoline-1-oxyl 3-oxide
(PTIO), chosen as a NO scavenger. After 3 h SNP
increased the nitrite levels in the culture medium of HT29
iNOS- cells, and such an increase was effectively abolished
by PTIO (Fig. 7A). Cells were checked for the expression
of eNOS, nNOS and iNOS proteins: neither PTIO nor SNP
changed the eNOS and nNOS levels when compared to
the untreated HT29 iNOS-, and iNOS remained absent
under each experimental condition (data not shown). As
far as the doxorubicin content and toxicity are concerned,
the intracellular drug accumulation and the extracellular
LDH release were significantly increased in the presence of
SNP, whereas the combination of PTIO and SNP reduced
both the drug content and toxicity to the control levels
(Fig. 7B, 7C). PTIO alone also slightly diminished the
intracellular doxorubicin accumulation. In drug-resistant
HT29-dx cells PTIO and SNP had the same effects on
nitrite synthesis (Fig 7A), intracellular doxorubicin accu-
mulation (Fig 7B) and cytotoxicity (Fig 7C) than in HT29
iNOS- cells.
Restoration of NO levels is per se sufficient to elicit the 
calreticulin translocation and the phagocytosis of HT29 
iNOS- cells
SNP per se was able to elicit the translocation of CRT on
the plasma membrane of HT29 iNOS- cells, as demon-
strated by flow cytometry analysis (Fig. 8A, 8C) and bioti-
nylation assays (Fig. 8D). Again the effect of the NO
donor was reduced by PTIO (Fig. 8). Neither SNP nor
PTIO changed the amount of total CRT in comparison
with the untreated HT29 iNOS- cells (Fig. 8D). Superim-
posable effects on CRT translocation were exerted by SNP
and PTIO on the drug-resistant HT29-dx cells (Fig 8B, 8C
and 8E). NO levels played a role also in the uptake of
tumour cells by DCs and in the further DCs-elicited lym-
phocytes activation: indeed the presence of SNP was suffi-
cient to increase the phagocytosis of HT29 iNOS- cells by
DCs (Fig 9A and 9B) and the subsequent expansion of
lymphocytes in response to DCs (Fig 9C), whereas the
addition of PTIO reversed these effects.
Discussion
Exerting a strong cytotoxic effect and enhancing the host
immune response against tumour cells are two goals of an
ideal anti-cancer therapy, which should improve the effi-
cacy of the conventional treatments, like chemotherapy
and radiotherapy, and improve the patients prognosis
[13].
The anthracyclines family, in particular doxorubicin, are
among the first therapeutic choices in solid tumours and
are the only known chemotherapeutics agents capable of
not only reduce the tumour cell mass, but also confer long
term protection against recurrent tumour [3,4,14], an
effect mediated by dendritic cells (DCs). DCs capture
tumour cells and present to T-cells the antigen epitopes on
class I MHC, thus cross-priming CD8 T lymphocytes. Anti-
gen capturing is property of immature DC (iDC), whereas
antigen presentation is a characteristic of the lymph node
migrating mature DC. The context in which the tumour is
captured by iDC dictates its immunogenicity, a para-
mount role being played by molecules induced by death
agents. Calreticulin has been shown to be translocated on
plasma membrane by anthracyclines and to trigger
tumour cells uptake by iDC [3,4,14]. Moreover doxoru-Molecular Cancer 2009, 8:108 http://www.molecular-cancer.com/content/8/1/108
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MRP3 nitration and intracellular doxorubicin accumulation in different cell lines and primary tumours sample Figure 4
MRP3 nitration and intracellular doxorubicin accumulation in different cell lines and primary tumours sample. 
(A, B, C) Western blot detection of nitrated MRP3, total MRP3, nitrated Pgp, total Pgp and GAPDH. A549, A549-dx, K562, 
K562-dx, MM98, OC99 and HP06 cells were incubated in the absence (CTRL) or in the presence of 5 μmol/L doxorubicin 
(doxo) for 24 h or 100 μmol/L SNP (SNP) for 3 h, then lysed and subjected to immunoprecipitation with an anti-nitrotyrosine 
polyclonal antibody. Western blotting for MRP3 and Pgp was performed on the immunoprecipitated proteins as reported in 
the Methods section. An aliquot of cell lysates was directly probed with an anti-Pgp or an anti-MRP3 antibody to detect total 
Pgp or MRP3. The expression of the housekeeping protein GAPDH was measured as equal control loading. The results shown 
here are representative of two similar experiments. (D) Cells were incubated in the absence (CTRL) or in the presence of 100 
μmol/L SNP, together with 5 μmol/L doxorubicin. The intracellular accumulation of the drug was measured fluorimetrically in 
cells (see Methods for details). The experiments were performed in triplicate and data are represented as mean ± SE (n = 3). 
Versus respective CTRL: * p < 0.02; versus A549-dx CTRL or K562-dx CTRL respectively: ° p < 0.02.
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bicin may exert a direct cytotoxic effect on transformed
cells with several mechanisms, e.g. by intercalating
amongst DNA bases, impairing the chromatin folding,
inhibiting the topoisomerase II activity and generating
reactive oxygen species [15]. At least part of the cytotoxic-
ity of this anthracycline is dependent on the synthesis of
NO [7], which can exert a pro-apoptotic effect on tumour
cells [9,16].
This work was aimed at investigating whether the cyto-
toxic and pro-immunogenic effects of doxorubicin rely on
the same mechanism, i.e. the synthesis of NO elicited by
the drug in tumour cells, through the induction of iNOS
gene [5,7]. We have previously observed that in drug-
resistant cancer cells doxorubicin fails to increase NO lev-
els [5]; we thus wondered whether the inability of tumour
cells to increase the NO production in response to the
drug, besides determining a chemoresistant phenotype,
also results in an immunoresistant status.
In order to investigate the importance of NO in chemo-
and immunoresistance, from the doxorubicin-sensitive
HT29 cells we developed the HT29 iNOS- cell line, which
was deprived of iNOS protein by a specific and stable RNA
interfering procedure. In this cell population doxorubicin
did not increase the NOS activity and the nitrite levels, as
a consequence of the iNOS  knocking-down. Regarding
NO synthesis, HT29 iNOS-  cells became functionally
equivalent to the HT29-dx cell line, a drug-resistant popu-
lation, in which doxorubicin is actively extruded by Pgp
and MRP3 membrane transporters. In HT29-dx cells the
drug has not sufficient time to accumulate and induce the
transcription of iNOS gene, and this results in the lack of
NO increase after doxorubicin exposure [5]. The charac-
terization of HT29, HT29-dx and HT29 iNOS- cells is sum-
marized in table 1.
Real Time-PCR and Western blotting experiments showed
the absence of the iNOS  mRNA and protein in HT29
iNOS- cells. On the other hand, we observed in this cell
line an increase of eNOS and nNOS isoforms, suggesting
that cells react to the absence of iNOS with an overexpres-
sion of the other two NOS isoforms. Such a crosstalk
among eNOS, nNOS and iNOS has been already
described: indeed it has been reported that when the
expression of iNOS is high, the levels of the constitutive
NOS isoforms are down-regulated, and vice versa [17-20].
This event may be due to a feedback inhibition exerted by
NO itself on constitutive NOS protein levels: for example
in endothelial cells the shear stress enhances the transcrip-
tion of eNOS gene in a NF-kB dependent way, but the NO
donor DPTA-NO, which nitrosylates NF-kB on p50 subu-
nit, prevents the NF-kB translocation and the eNOS
increase [21]. Doxorubicin is known to activate NF-kB [9]
and to induce the expression of iNOS [8]. It is conceivable
that the huge amounts of NO produced in response to
doxorubicin could inhibit the further activation of NF-kB
and limit the expression of eNOS in HT29 cells; on the
contrary, in HT29 iNOS- cells doxorubicin is free to acti-
vate NF-kB, but not to induce iNOS gene. Since the NO-
mediated inhibition on NF-kB is lacking in HT29 iNOS-
cells, NF-kB may translocate into the nucleus and increase
the transcription of eNOS gene in these cells. This mecha-
nism might explain why eNOS expression is increased in
HT29 iNOS- cells exposed to doxorubicin. Few data exist
on the reciprocal regulation of nNOS and iNOS [20], but
a similar mechanism may be hypothesized to explain also
the increase nNOS expression in HT29 cells silenced for
iNOS. Although in our experimental conditions eNOS
and nNOS proteins were up-regulated, the global NOS
activity in HT29 iNOS- cells was not higher than in control
HT29 cells. This is not surprising, because eNOS and
nNOS proteins have a very low basal activity and are both
Ca2+/calmodulin-dependent; therefore they reach a maxi-
mal activity only when Ca2+ is increased within cells [22],
which is not the case of untreated HT29 iNOS- cells. Thus
it seems conceivable that eNOS and nNOS, although
over-expressed, were poorly active in HT29 iNOS- cells.
To evaluate whether the lack of NO, independently from
the underlying molecular mechanism (increased doxoru-
bicin efflux, as occurs in HT29-dx cells, or absence of
iNOS enzyme, as seen in HT29 iNOS- cells), was impor-
tant for chemo- and immunoresistance, we examined the
doxorubicin accumulation and cytotoxicity in wild-type
HT29 cells, in HT29-dx cells and in HT29 iNOS- cells. The
three cell lines markedly differed in the amount of drug
efflux pumps: both Pgp and MRP3 were low in the paren-
tal HT29 and in the iNOS-silenced cells derived from
HT29, and were over-expressed in HT29-dx cells. How-
ever, HT29 iNOS- had the same behaviour of HT29-dx
cells in accumulating low amount of doxorubicin and
being poorly damaged by the drug. This result suggests
that NO regulates the cell resistance to doxorubicin, inde-
pendently from the absolute amount of the drug efflux
pumps.
We hypothesized that the low intracellular accumulation
of doxorubicin observed in HT29 iNOS- cells was a conse-
quence of an increased activity of the drug efflux trough
Pgp and MRP3, as occurs in HT29-dx cells. Indeed NO can
enhance doxorubicin accumulation by nitrating tyrosine
residues of the MRP3 pump [5,9,10]. Because HT29 iNOS-
cells had the same amount of MRP3 and Pgp of HT29
cells, we checked whether a different amount in nitrated
tyrosine residues of MRP3, which is related to a different
activity of the pump [5,9,10], may explain the differences
in doxorubicin accumulation between these two cells
lines. Indeed, doxorubicin did increase the nitration of
MRP3 pump only in HT29 cells, in accordance with theMolecular Cancer 2009, 8:108 http://www.molecular-cancer.com/content/8/1/108
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higher NO levels observed after the exposure to the drug;
on the contrary, HT29 iNOS- cell line did not show any
nitrated tyrosine residues on MRP3, as well as HT29-dx
cells. It is conceivable that NO exerts a restraint on MRP3
activity, therefore the lack of NO synthesis allows the
MRP3 to freely pump doxorubicin out, limiting its intrac-
ellular accumulation and toxicity, and inducing a chem-
oresistant phenotype. Although Pgp is a second crucial
transporter for doxorubicin, in our experimental condi-
tions no nitration has been detected. The protein amounts
and localization, the tyrosine accessibility and number,
the presence of particular amino acidic sequences around
the tyrosines are considered critical factors in determining
the nitration of a protein [23]. The lower abundance of
Pgp respect to MRP3 or the lower number of accessible
tyrosine on Pgp may account for the absence of nitrotyro-
sine on Pgp in HT29 cells.
To our knowledge, no epidemiological data exist about
the frequency of nitration of MRP3 in colon cancer. How-
ever, the nitration of cell proteins, such as tubulin, actin
and β-catenin, has been reported in inflammatory bowel
diseases [24] and in colon cancers [25,26], where a sus-
tained NO synthesis (mainly due to the activation of
iNOS) occurred. MRP3 is particularly abundant in colon
tumour specimens [27,28]; therefore we hypothesize that
its nitration, e.g. following the activation of iNOS by
inflammatory stimuli of tumour microenvironment or by
doxorubicin, is not so rare in human colon cancers. Our
work shows that the nitration of the drug efflux transport-
ers occurs in cell lines other than colon and is detectable
also in primary tumour samples. In each tissue a different
pathway of nitration of Pgp or MRP3 occurs: the discrep-
ancies may depend on the relative amounts of each trans-
porter or on the accessibility of the target tyrosines, which
may vary among the isoforms of Pgp and MRP3 present in
different tissues. However, independently from which
transporter is nitrated, the nitration of either Pgp or MRP3
leads to a decrease of the drug efflux and revert the resist-
ance to doxorubicin.
When activated by doxorubicin, iNOS can produce micro-
molar amounts of NO [29], which at such high levels may
act as a anti-cancer agent by impairing the aerobic mito-
chondrial metabolism, inhibiting the ribonucleotide
reductase enzyme and directly damaging DNA via a nitro-
sative and oxidative stress [16,29]. NO is also considered
an immuno-modulatory agent at tumour sites, where it
can differently regulate the activity of the host immune
system [30]. Starting from the observation that part of the
doxorubicin anti-cancer effects relies on the activation of
immune system cells, through CRT exposure and DC
recruitment, we investigated which role NO may play in
these events.
Doxorubicin induced CRT exposure on the cell mem-
brane in HT29 cells but not in HT29-dx and in HT29
iNOS- cells. In keeping with the CRT surface levels, doxo-
Detection of surface calreticulin in HT29, HT29-dx and HT29 iNOS- cells Figure 5
Detection of surface calreticulin in HT29, HT29-dx and HT29 iNOS- cells. Cells were grown in absence (CTRL) or 
presence of 5 μmol/L doxorubicin (doxo) for 24 h and subjected to the following investigations. (A, B) FACS analysis of surface 
CRT. Negative controls, with non-immune isotypic antibodies, are shown in A by green outline. The figures shown here are 
representative of three similar experiments, performed in triplicate. In panel B the percentage of cells positive for surface cal-
reticulin is represented as mean ± SE in all experiments. Versus HT29 CTRL: * p < 0.005. (C) Western blot detection of sur-
face CRT and total CRT. The measurement of CRT associated with the plasma membrane was performed in a biotinylation 
assay as described in the Methods section. Under the same experimental conditions, an aliquot of cells was lysed and ultracen-
trifuged to detect the total CRT amount. The results shown here are representative of two similar experiments.
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rubicin induced the tumour cells phagocytosis by DCs in
the chemosensitive HT29 cells, but not in chemoresistant
HT29-dx cells and HT29 iNOS- cells. The translocation of
calreticulin and the subsequent tumor cells uptake by
immature DCs are the first steps along a doxorubicin-
induced DCs stimulatory pathway. Indeed, when chemo-
sensitive HT29 cells were exposed to the drug, they were
engulfed with higher efficiency by DCs, with a consequent
increase of alloantigen presenting activity by DCs. On the
contrary, doxorubicin treatment of HT29-dx and HT29-
iNOS- cells failed to induce CRT translocation, did not
change the uptake of the tumour and had no effect on the
alloantigen presenting activity of DCs. In the absence of
DCs, tumour cells alone were incompetent to trigger lym-
phocytes proliferation, despite the high levels of CRT, as
occurred in HT29 cells treated with doxorubicin. These
results suggest that doxorubicin requires the presence of
local DCs, which actively phagocyte CRT-positive tumor
cells and bona fide cross-present the tumor antigens [4],
to recruit host lymphocytes against the tumor and exert a
significant pro-immunogenic effect. Of interest in our
study is the description of the ability of doxorubicin to
reverse the immunosuppression exerted by the HT29 cells
on functional maturation of DCs, an event in keeping
with our previous findings on a gastric cell line [31], a
renal carcinoma [32] and a prostate carcinoma cell line
[33].
Despite significant changes in the CRT exposed on the
plasma membrane we did not observe any variation in
total CRT. This result suggests that the change in CRT lev-
els on the cell surface should be due to a translocation
from ER to the plasma membrane, rather than to a de novo
synthesis of the protein. Indeed most CRT usually resides
in the ER and is absent on the plasma membrane of
untreated cells, as we detected in control HT29, HT29-dx
and HT29 iNOS- cells. It has been suggested that also
small variations in the CRT amount in plasma membrane
may be sensed as an effective "eat me signal" and produce
dramatic effects on DCs recruitment [4].
At the light of our results, we may hypothesize that the
lack of CRT exposure following doxorubicin incubation in
HT29-dx and HT29 iNOS- cells is mainly due to the low
intracellular drug content, which is insufficient to elicit
the translocation of CRT; on the other hand, we cannot
exclude that in these cells the lack of CRT exposure may be
a consequence of the insufficient synthesis of NO, which
has already been shown to enhance the translocation of
proteins from cytosol to plasma membrane [12].
To clarify whether NO mediates the doxorubicin-induced
exposure of CRT, we changed the NO levels in the doxo-
Phagocytic and alloantingenic presenting activity of DCs  loaded with HT29, HT29-dx and HT29 iNOS- cells Figure 6
Phagocytic and alloantingenic presenting activity of 
DCs loaded with HT29, HT29-dx and HT29 iNOS- 
cells. After a 24 h incubation in the absence (CTRL) or in the 
presence of 5 μmol/L doxorubicin (doxo), the tumour cells 
were green-stained with PKH2-FITC and subjected to the 
phagocytosis assay as described in the Methods section. The 
dot plot analysis of a phagocytosis assay, representative of 
three similar experiments performed in duplicate, is shown in 
panel A. In panel B the phagocytic index is represented as 
mean ± SE of all the experiments. Versus HT29 CTRL: * p < 
0.02. C. DCs unloaded (DC), loaded with untreated tumour 
cells (CTRL) or loaded with doxorubicin-treated tumour cells 
(dox), in the same experimental conditions of panel B, were 
treated with mitomycin C and co-cultured with PBMCs, con-
taining the allogenic lymphocytes. At day 4 cells were labelled 
with [methyl-3H]deoxythymidine and the cpm were evalu-
ated in a β-counter. The [methyl-3H]deoxythymidine incor-
poration of lymphocytes alone were 1985.33 ± 298.19 cpm. 
The Proliferation Index of each culture was calculated as 
detailed in the Methods section. The experiments were per-
formed in triplicate and the results are expressed as mean ± 
SE from two experiments with lymphocytes from different 
donors. Versus DC: * p < 0.01; versus HT29 CTRL: ° p < 
0.05.
CTRL doxo CTRL doxo CTRL doxo
0
1
2
3
P
h
a
g
o
c
y
t
i
c
 
i
n
d
e
x
*
HT29 HT29
  -dx
HT29
iNOS-
B
C
DC CTRL dox CTRL dox CTRL dox
0
5
10
15
20
l
y
m
p
h
o
c
y
t
e
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
i
n
d
e
x
+HT29 +HT29-dx +HT29 iNOS-
DC DC DC
*
°
* *
AMolecular Cancer 2009, 8:108 http://www.molecular-cancer.com/content/8/1/108
Page 11 of 18
(page number not for citation purposes)
rubicin-resistant and iNOS-deprived cells: if NO is critical
for the doxorubicin immunogenic effects, we should be
able to observe the translocation of CRT followed by the
phagocytosis of HT29 iNOS- cells, simply by increasing
the NO level. To this purpose we chose the NO-donor
SNP, which releases huge amounts of NO after interacting
with reducing agents, such as intracellular thiols [16]. SNP
increased the nitrite levels, the intracellular accumulation
and the toxicity of doxorubicin in HT29 iNOS- cells. These
effects were prevented by the co-incubation with an equi-
molar concentration of the NO-scavenger PTIO. Most
importantly, SNP alone up-regulated the CRT exposure on
the cell membrane of the iNOS  deprived cells and
enhanced the cells uptake by DCs, as well as the activation
of lymphocytes recognizing the alloantigen presented by
DCs. Taken as a whole, these results show that in the
chemoresistant HT29 iNOS- cell line a NO donor repro-
duces the effects exerted by doxorubicin in the chemosen-
sitive HT29 cells. PTIO succeeds in reducing the CRT
exposure and the cell phagocytosis induced by SNP, trans-
forming again the immunogenic phenotype of HT29
iNOS-  cells into non-immunogenic phenotype. We
obtained the same effects on doxorubicin accumulation
and CRT exposure in HT29-dx cells. These results suggest
that NO levels are crucial in modulating the immune- and
chemoresistance in human colon cancer cells. The mech-
anism by which NO mediates the CRT translocation is
currently under investigation in our laboratory: prelimi-
nary data suggest an involvement of the guanylate cyclase/
protein kinase G pathway and of the actin fibers cytoskel-
eton remodelling in such a translocation.
Conclusion
To our knowledge, this is the first work showing that
chemo- and immunoresistance may be strictly associated
in cancer cells. Our results suggest that NO is a mediator
for these events and that through a common strategy (aug-
menting NO levels), both chemo- and immunoresistance
can be reversed. Notably NO-releasing drugs are widely
used in the therapy of cardiovascular diseases and NO-
donors are objects of intensive investigations as potential
anticancer drugs, as single cytotoxic agents as well as in
combination with standard radio- and chemotherapy
[34,35]. Our findings that these compounds are involved
in both the anticancer and pro-immunogenic effects of
anthracyclines may pave the way to their future applica-
tion in the therapy of solid tumours.
Methods
Materials
Foetal bovine serum (FBS), penicillin-streptomycin (PS)
and RPMI 1640 were supplied by Sigma Chemical Co (St.
Louis, MO), plasticware for cell culture was from Falcon
(BD Biosciences, Bedford, MA). Electrophoresis reagents
were obtained from Bio-Rad Laboratories (Hercules, CA),
the protein content of cell monolayers and cell lysates was
assessed with the bicinchoninic acid kit from Sigma
Chemical Co. When not otherwise specified, all the other
reagents were purchased from Sigma Chemical Co.
Cells
Human colon cancer cells (HT29 cell line, provided by
Istituto Zooprofilattico Sperimentale "Bruno Umbertini",
Brescia, Italy) were cultured in RPMI 1640 medium sup-
plemented with 10% FBS, 1% PS, and 1% L-glutamine
and maintained in a humidified atmosphere at 37°C and
5% CO2.
A subpopulation of HT29 cells, named HT29-dx, was cre-
ated according to the methods of Riganti et al. [5] and
subsequently cultured in RPMI 1640 medium containing
150 nmol/L doxorubicin as "maintenance dose". HT29-
dx cells exhibited a higher amount of Pgp and MRP3, a
significantly lower intracellular accumulation of doxoru-
bicin after a drug bolus (5 μmol/L) and were more resist-
ant to the drug's toxic effects, as previously described [5].
Human doxorubicin-sensitive lung cancer A549 cells
(purchased from Istituto Zooprofilattico Sperimentale
"Bruno Umbertini", Brescia, Italy) and human doxoru-
bicin-resistant lung cancer A549-dx cells (selected from
the parental A549 cells after 30 passages in medium con-
taining 50 nM doxorubicin) were grown in HAM'S F12
medium, with 10% FBS, 1% PS, and 1% L-glutamine.
Human doxorubicin-sensitive chronic myelogenous leu-
kaemia cells K562 (from Istituto Zooprofilattico Speri-
mentale "Bruno Umbertini") and human doxorubicin-
resistant chronic myelogenous leukaemia cells K562-dx
(obtained after 30 passages of parental K562 in medium
containing 25 pM doxorubicin) were cultured in RPMI
1640 medium, in the presence of 10% FBS, 1% PS, and
1% L-glutamine. MM98 and OC99 cells, two primary
malignant mesothelioma cell cultures established from
the pleural effusion of two patients with histologically
confirmed malignant mesotelioma, were already
described [11]. HP06 cells, derived from the peritoneal
metastasis of a female patient with an invasive breast can-
cer, was a gift from Prof. Anna Sapino (Department of
Biomedical Sciences and Oncology, University of Turin,
Italy); cells were grown in DMEM medium with 10% FBS,
1% PS, and 1% L-glutamine and were used at passages 2-
4.
iNOS siRNA Transfection
200,000 cells were plated in 35-mm-diameter Petri dishes
and cultured in RPMI 1640 medium. After 24 h, the
medium was removed and the cells were incubated for 6
h with 250 μL ESCORT DNA mix (Sigma Chemical Co.),
containing 15 μL ESCORT reagent and 1 μg pLKO.1-puro
vector, in which the iNOS MISSION shRNA (codeMolecular Cancer 2009, 8:108 http://www.molecular-cancer.com/content/8/1/108
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10270809MN, Sigma Chemical Co.) was subcloned.
Then the medium was removed and 2 mL RPMI 1640
(with 20% FBS and 1% PS) were added. After 48 h from
the transfection, the cells were cultured in RPMI 1640
containing 2 nmol/L puromycin, to select the clones
silenced for iNOS gene. To verify that the silencing was
successful, we checked the iNOS  mRNA levels by Real
time-PCR, the iNOS protein expression by Western blot-
ting and the NO synthesis as reported below. To ascertain
the specificity of the silencing experimental procedure, an
aliquot of HT29 cells was treated with 1 μg pLKO.1-puro
vector containing a scrambled non-targeting 20-25 nucle-
otide shRNA, instead of iNOS shRNA, and the iNOS
expression evaluated in this cell population was used as a
negative control.
Nitrite Production
Confluent monolayers in 35-mm-diameter Petri dishes
were incubated in fresh medium under the experimental
conditions indicated in Results. Nitrite production was
measured by adding 0.15 mL of cell culture medium to
0.15 mL of Griess reagent in a 96-well plate, and after a 10
min incubation at 37°C in the dark, the absorbance was
detected at 540 nm with a Packard EL340 microplate
reader (Bio-Tek Instruments, Winooski, VT). A blank was
prepared for each experiment in the absence of cells, and
its absorbance was subtracted from that obtained in the
presence of cells. Nitrite concentration was expressed as
nanomoles of nitrite/mg cell protein.
Measurement of NOS Activity
To measure NOS activity, the procedure described in
Ghigo et al. [36] was followed. The cells were detached
with 0.05% v/v trypsin, washed with PBS, re-suspended at
the concentration of 100 μg cell proteins in 0.6 mL of 20
mmol/L Hepes buffer (pH 7.2) and sonicated with one 10
s burst, using a Labsonic Sonicator (Hielscher, Teltow,
Germany). 15 μL of lysate was withdrawn to asses the pro-
tein content. The protease inhibitors pepstatin (75 μmol/
L) and leupeptin (20 μmol/L) were added to the cell
lysate, which was then mixed with the following reagents
in a 500 μL final volume: 0.2 mmol/L NADP+, 360 μmol/
L L-arginine, 2 μmol/L tetrahydrobiopterin, 0.3 mmol/L
CaCl2, 0.2 mmol/L dithiothreitol, 1.8 mmol/L MgCl2,
0.17 mmol/L glucose 6-phosphate, and 40 mU/mL glu-
cose 6-phosphate dehydrogenase (G6PD; from Saccaromy-
ces cerevisiae; EC 1.1.1.49). The NOS/G6PD reaction
mixture described above was incubated at 37°C for 3 h,
then heated at 100°C for 5 min to inactivate G6PD. To
oxidize the remaining NADPH, which might interfere
with the subsequent Griess reaction, the mixture was incu-
bated with 10 mU/mL L-lactate dehydrogenase (from pig
muscle; EC 1.1.1.27) and 300 μmol/L sodium pyruvate at
Effect of SNP and PTIO on nitrite levels and doxorubicin tox- icity in HT29 iNOS- cells Figure 7
Effect of SNP and PTIO on nitrite levels and doxoru-
bicin toxicity in HT29 iNOS- cells. HT29 iNOS- cells and 
HT29-dx cells were incubated for 3 h in the absence (CTRL) 
or presence of PTIO (100 μmol/L), SNP (100 μmol/L) or 
both (PTIO+SNP), then subjected to the following investiga-
tions. (A) Nitrite levels in extracellular medium were meas-
ured by Griess method as reported in the Methods section. 
Measurements were done in triplicate and data are repre-
sented as mean ± SE (n = 3). Versus CTRL: * p < 0.05; versus 
SNP: ° p < 0.05. (B). Intracellular accumulation of doxoru-
bicin was measured fluorimetrically in cells incubated in the 
absence (CTRL) or in the presence of PTIO, SNP and 
PTIO+SNP, together with 5 μmol/L doxorubicin (see Meth-
ods section). The experiments were performed in triplicate 
and data are represented as mean ± SE (n = 3). Versus CTRL: 
* p < 0.002; versus SNP: ° p < 0.01. (C) The release of LDH 
in the cell culture medium was measured in triplicate under 
the same experimental conditions of point B. In the absence 
of doxorubicin, neither PTIO nor SNP significantly changed 
the extracellular activity of LDH towards control cells (data 
not shown). Data are represented as mean ± SE (n = 4). Ver-
sus CTRL: * p < 0.02; versus SNP: ° p < 0.01.
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37°C for 5 min. The nitrite production was measured
using the Griess reagent as described. Blanks were pre-
pared by replacing the cell lysate with Hepes solution, in
the NOS/G6PD reaction mix, which was subjected to the
same experimental procedure used for samples contain-
ing lysate. The NOS activity was expressed as nanomoles
nitrites/min/mg protein.
Real Time-PCR
Total RNA was obtained as previously described [37]. 5 μg
of RNA was reverse-transcribed by 200 U of M-MLV
reverse transcriptase (Invitrogen, Milan, Italy), in the pres-
ence of 40 U/μL RNAseOUT (Invitrogen). Quantitative
Real Time-PCR was carried out using IQ™ SYBR Green
Supermix (Bio-Rad), according to the manufacturer's
instructions. The same cDNA preparation was used for the
quantitation of iNOS and GAPDH, used as an housekeep-
ing gene. The sequences of the primers of iNOS were: 5'-
ACAACAAATTCAGGTACGCTGTG-3', 5'-TCTGATCAAT-
GTCATGAGCAAAGG-3'; the sequences of the GAPDH
primers were: 5'-GAAGGTGAAGGTCGGAGT-3', 5'-CAT-
GGTGGAATCATATTGGAA-3'. PCR amplification for
iNOS was: 1 cycle of denaturation at 94°C for 3 min, 45
cycles of denaturation at 94°C for 30 s, annealing at 58°C
for 30 s and synthesis at 72°C for 30 s; for GAPDH: 1 cycle
of denaturation at 94°C for 3 min, 40 cycles of denatura-
tion at 94°C for 30 s, annealing at 58°C for 30 s and syn-
thesis at 72°C for 30 s. The relative quantitation of each
sample was performed comparing the Pgp PCR product
with the GAPDH product, using the Bio-Rad Software
Gene Expression Quantitation (Bio-Rad).
Intracellular Doxorubicin Accumulation
Cells were grown in 35-mm-diameter Petri dishes and
incubated as reported in the Results section in RPMI 1640
medium containing 5 μmol/L doxorubicin. Then cells
were washed twice with PBS and detached with trypsin/
EDTA. The cells were centrifuged for 30 s at 13,000 × g, re-
suspended in 1 mL of a 1:1 mixture of ethanol/0.3 N HCl
and sonicated. The protein content of the cell lysates was
measured and the amount of intracellular doxorubicin
was detected using a PerkinElmer LS-5 spectrofluorimeter
(PerkinElmer, Waltham, MA). Excitation and emission
wavelengths were 475 and 553 nm, respectively. A blank
was prepared in the absence of cells in each set of experi-
ments and its fluorescence was subtracted from that meas-
ured in each sample. Fluorescence was converted in ng
doxorubicin/mg cells proteins using a calibration curve
prepared previously.
Extracellular LDH Activity
To verify the cytotoxic effect of doxorubicin, the extracel-
lular medium was centrifuged at 12,000 × g for 15 min to
pellet cellular debris, whereas cells were washed with fresh
medium, detached with trypsin/EDTA, re-suspended in
0.2 ml of 82.3 mmol/L triethanolamine phosphate-HCl
(pH 7.6) and sonicated on ice with two 10 s bursts. LDH
activity was measured in the extracellular medium and in
the cell lysate: 50 μl of supernatant from extracellular
medium or 5 μL of cell lysate were incubated at 37°C with
5 mmol/L NADH. The reaction was started by adding 20
mmol/L pyruvic acid and was followed for 6 min, meas-
uring absorbance at 340 nm with Packard EL340 micro-
plate reader (Bio-Tek Instruments). The reaction kinetics
was linear throughout the time of measurement. Both
intracellular and extracellular enzyme activity was
expressed in μmol NADH oxidized/min/dish, then extra-
cellular LDH activity was calculated as percentage of the
total LDH activity in the dish.
Flow Cytometry Analysis
Cells grown at confluence on 35-mm-diameter Petri
dishes were washed twice with PBS, detached with Cell
Dissociation Solution (Sigma), rinsed with 1 mL of 0.25%
w/v PBS-bovine serum albumin (BSA) and centrifuged at
10,000 × g for 5 min. The cells were incubated for 45 min
at 4°C with an anti-CRT rabbit polyclonal antibody (cat-
alogue number PA3-900, ABR-Affinity BioReagents Inc.,
Golden, CO), diluted 1:500 in 100 μL of PBS-BSA. After
this time the cells were washed twice with PBS-BSA and
incubated with 100 μL anti-rabbit fluorescein isothiocy-
anate (FITC)-conjugated antibody (diluted 1:50 in PBS-
BSA, Sigma Chemical Co.) for 30 min at 4°C in the dark.
The samples were then washed twice in PBS-BSA, fixed
with 0.2 mL of 2% w/v paraformaldehyde and re-sus-
pended in 500 μL PBS-BSA. The fluorescence of each sam-
ple was recorded using a FACS-Calibur system (Becton
Dickinson, Bedford, MA). For each analysis 10,000 events
were collected; the green fluorescence of FITC was
detected using a 530 nm band pass filter. The percentage
of fluorescent cells was calculated by the Cell Quest soft-
ware (Becton Dickinson). Control experiments included
incubation of cells with non-immune isotypic antibodies
followed by the appropriate labelled secondary antibod-
ies. Since doxorubicin has a strong autofluorescence
which might lead to the misinterpretation of flow cytom-
etry results, we validated FACS experiments by measuring
the CRT exposure in biotinylation assays, as reported
below.
Western Blot Analysis
Cells grown at confluence on 60-mm-diameter Petri
dishes were washed twice with PBS, then lysed in sample
buffer heated at 99°C (25 mmol/L Hepes, 135 mmol/L
NaCl, 1% v/v Nonidet P-40, 5 mmol/L EDTA, 1 mmol/L
EGTA, 1 mmol/L ZnCl2 and 10% v/v glycerol) and soni-
cated with one 10 s burst. After centrifugation (13,000 × g
for 15 min), the protease inhibitor cocktail set III (100
mmol/L AEBSF, 80 μmol/L aprotinin, 5 mmol/L bestatin,
1.5 mmol/L E-64, 2 mmol/L leupeptin, and 1 mmol/LMolecular Cancer 2009, 8:108 http://www.molecular-cancer.com/content/8/1/108
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pepstatin; Calbiochem, La Jolla, CA), 2 mmol/L phenyl-
methylsulfonyl fluoride and 1 mmol/L NaVO4  were
added to the supernatant. Whole cell extracts containing
equal amounts of proteins (30 μg) were separated by SDS-
PAGE, transferred to PVDF membrane sheets (Immo-
bilon-P, Millipore, Bedford, MA) and probed with the fol-
lowing antibodies, diluted in 1% w/v PBS-BSA: anti-iNOS
(catalogue number 610332 BD Biosciences, blocking pep-
tide: aminoacids 961-1144 of mouse iNOS; rabbit poly-
clonal, diluted 1:1000), anti-eNOS (catalogue number
610297 BD Biosciences, blocking peptide: aminoacids
1025-1203 of human eNOS; mouse monoclonal, diluted
1:500), anti-nNOS (catalogue number 610308 BD Bio-
sciences, blocking peptide: aminoacids 1095-1289 of
human nNOS; mouse monoclonal, diluted 1:500), anti-
Pgp (catalogue number sc-8313, Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA; blocking peptide: aminoacids
1040-1280 of human Pgp; rabbit polyclonal, diluted
1:250), anti-MRP3 (catalogue number sc-5774, Santa
Cruz Biotechnology Inc.; blocking peptide sc-5774P
raised against aminoacids 1-50 of human MRP3; goat pol-
yclonal, diluted 1:250), anti-GAPDH (catalogue number
sc-25778, Santa Cruz Biotechnology Inc.; blocking pep-
tide: aminoacids 1-335 of human GAPDH; rabbit polyclo-
nal, diluted 1:500). After an overnight incubation, the
membrane was washed with PBS-Tween 0.1% v/v and
subjected for 1 h to a horseradish peroxidase-conjugated
anti-rabbit (catalogue number 170-6515, Bio-Rad,
diluted 1:3000 in PBS-Tween with 5% w/v non-fat dry
milk) or anti-mouse antibody (catalogue number 170-
6516, Bio-Rad, diluted 1:3000 in PBS-Tween with 5% w/
v non-fat dry milk), or to an anti-goat antibody (catalogue
number sc-2384, Santa Cruz Biotechnology Inc., diluted
1:1000 in PBS-Tween with non-fat dry milk 5%). The
Effect of SNP and PTIO on calreticulin exposure in HT29 iNOS- cells Figure 8
Effect of SNP and PTIO on calreticulin exposure in HT29 iNOS- cells. HT29 iNOS- cells and HT29-dx cells were incu-
bated for 3 h in the absence (CTRL) or in the presence of PTIO (100 μmol/L), SNP (100 μmol/L) or both (SNP+PTIO) for 3 h, 
and then the surface CRT was investigated by the following procedures. (A, B, C) FACS analysis of surface CRT. The negative 
controls, with non-immune isotypic antibodies, are shown by green outline in panel A and B. The figures shown here are rep-
resentative of three similar experiments, done in triplicate. In panel C the percentage of cells positive for surface CRT is rep-
resented as mean ± SE in all experiments. Versus CTRL: * p < 0.05; versus SNP: ° p < 0.05. (D, E) Western blot detection of 
surface CRT and total CRT in HT29 iNOS- cells and HT29-dx cells after a biotinylation assay (see Methods for details). Total 
CRT was detected in an aliquot of cells incubated under the same experimental conditions of the biotinylation assay, subjected 
to ultracentifugation and Western blot analysis. The results shown here are representative of two similar experiments, with 
superimposable results.
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membrane was washed again with PBS-Tween and pro-
teins were detected by enhanced chemiluminescence
(PerkinElmer).
To analyse the presence of nitrated proteins, the whole cell
extract was subjected to an overnight immunoprecipita-
tion using a rabbit polyclonal anti-nitrotyrosine antibody
(catalogue number AB5411, Millipore; diluted 1:100 in
blocker non-fat dry milk 1%). Immunoprecipitated pro-
teins were separated by 7% SDS-PAGE, transferred to
PVDF membrane sheets and probed with anti-Pgp and
anti-MRP3 antibodies, as previously described.
To assess the whole cells content of calreticulin, cells were
solubilized in lysis buffer (10 mmol/L Tris-HCl, 100
mmol/L NaCl, 20 mmol/L KH2PO4, 30 mmol/L EDTA, 1
mmol/L EGTA, 250 mmol/L sucrose; pH 7.5), supple-
mented with protease inhibitor cocktail set III, 250 mmol/
L NaF, 100 mmol/L NaVO4 and 100 mmol/L phenylmeth-
ylsulfonyl fluoride. The cell lysates were centrifugated at
Phagocytic and alloantingenic presenting activity of DCs loaded with HT29 iNOS- cells in the presence of SNP and PTIO Figure 9
Phagocytic and alloantingenic presenting activity of DCs loaded with HT29 iNOS- cells in the presence of SNP 
and PTIO. Cells were incubated for 3 h in fresh medium (CTRL), PTIO (100 μmol/L), SNP (100 μmol/L) or both (SNP+PTIO), 
then stained with PKH2-FITC and co-incubated with DCs for the phagocytosis assay, as described in the Methods section. The 
dot plot analysis of a phagocytosis assay, representative of three similar experiments performed in duplicate, is shown in panel 
A. In panel B the phagocytic index is represented as mean ± SE of all the experiments. Versus CTRL: * p < 0.05; versus SNP: ° 
p < 0.05. C. Unloaded DCs (DC) or DCs loaded with HT29 iNOS- cells in the same experimental conditions of panel B were 
inhibited by mitomycin and the DNA synthesis of co-cultured allogenic lymphocytes was measured as reported in the legend of 
Figure 6. The Proliferation Index was measured as described in the Methods section. The [methyl-3H]deoxythymidine incorpo-
ration of lymphocytes alone were 899.33 ± 96.56. The experiments were performed in triplicate and the results are expressed 
as mean ± SE from four experiments with lymphocytes from different donors. Versus DC: * p < 0.02; versus CTRL: ° p < 0.02; 
versus SNP: ° p < 0.05.
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13,000 × g for 5 min at 4°C and the supernatants were
centrifuged for 60 min at 100,000 × g. The samples were
re-suspended in 300 μL lysis buffer of which 15 μL was
used to measure the protein content. 10 μg of the cell
extracts were separated by 10% SDS-PAGE, transferred to
a PVDF membrane sheet and probed with the anti-CRT
rabbit polyclonal antibody, diluted 1:1000 in PBS-BSA
1%.
For the detection of calreticulin in the plasma membrane,
a cell surface protein isolation kit was used (Thermo
Fisher Scientific Inc., Rockford, IL). The cells were washed
with PBS, labelled with EZ-Link®  Sulfo-NHS-SS-Biotin
(Thermo Fisher Scientific Inc.) for 30 min at 4°C, then
rinsed with the quenching solution of the kit and washed
twice in PBS. The pellet was re-suspended in the lysis
buffer provided by the kit, supplemented with protease
inhibitor cocktail set III and sonicated on ice with five 1 s
bursts. The lysates were incubated 30 min on ice, while
vortexing every 5 min for 5 s, then additionally sonicated
and centrifugated at 10,000 × g for 2 min at 4°C. The iso-
lation of biotinylated cell surface proteins was performed
with an affinity chromatography procedure, using the
Immobilized neutrAvidin™ Gel (agarose beads; Thermo
Fisher Scientific Inc.). The bound proteins were released
by incubating the extracts with sample buffer containing
50 mmol/L DTT. Finally the biotinylated proteins were
separated by 10% SDS-PAGE, transferred to a PVDF mem-
brane sheet and probed with the anti-CRT rabbit polyclo-
nal antibody as reported.
Generation of DC from peripheral blood monocytes
Immature dendritic cells were generated as described [32].
Peripheral blood mononuclear cells (PBMC) were iso-
lated from heparinized blood of voluntary healthy donors
by standard density gradient centrifugation (Histopaque-
1077), washed with RPMI 1640 medium supplemented
with 5 mmol/L EDTA and 2% heat-inactivated FBS, and
suspended at 5 × 106/ml in RPMI 1640 medium supple-
mented with 10% FBS. After 2 h incubation at 37°C in a
humidified 5% CO2 incubator, non-adherent cells were
removed, whereas adherent cells (monocytes) were cul-
tured in the above complete medium supplemented with
GM-CSF (1000 U/ml) and IL-4 (1000 U/ml). Cytokines
were replaced on day 3 and iDC were collected on day 6.
Phagocytosis Assay
The tumor cells were green-stained with PKH2-FITC
(Sigma Chemical Co.) according to the manufacturer's
instructions. After 4 h the cells were washed and incu-
bated for 20 h at 37°C with 1 × 105 iDC at a 1:1 ratio, and
the mixed culture was stained with the phycoerythrin
(PE)-conjuganted anti-CD80 antibody (BD Bioscience)
for 20 min at 4°C. Phagocytosis of tumour cells by iDC
was assessed by flow cytometric analysis as the percentage
of double-stained (FITC plus PE) versus red (PE) stained
cells on a total of 10,000 events, using the DIVA software
(FacsCanto system, BD). In parallel a phagocytosis assay
was performed by co-incubating iDC and tumour cells at
4°C, instead of 37°C. The percentage of double-stained
cells obtained after the incubation at 4°C was subtracted
from that obtained after a 37°C incubation. The phagocy-
tosis rate was expressed as phagocytic index, calculated as
reported by Obeid et al. [4].
Alloantigen presentation assay
The assay was performed as reported in [38], with minor
modifications. DCs that had incubated 20 h with the
Table 1: Characterization of HT29, HT29-dx and HT29 iNOS- cells
Parameters HT29 cells HT29-dx cells HT29 iNOS- cells
Doxorubicin-induced
expression of iNOS protein
Increased Absent Absent
Doxorubicin-induced
expression of iNOS mRNA
Increased Absent Absent
Doxorubicin-induced
NOS activity
High Low Low
Intracellular doxorubicin
Accumulation
High Low Low
LDH release after
Doxorubicin
High Low Low
MRP3 expression Low High Low
Doxorubicin-induced
MRP3 nitration
Present Absent Absent
Pgp expression Low High Low
Doxorubicin-induced
Pgp nitration
Absent Absent Absent
Doxorubicin-induced
CRT translocation
Increased Absent Absent
Doxorubicin-induced
DC activation
Increased Absent AbsentMolecular Cancer 2009, 8:108 http://www.molecular-cancer.com/content/8/1/108
Page 17 of 18
(page number not for citation purposes)
untreated/treated tumour cells or cultured alone were
treated for 2.5 h with 10 μg/ml mitomycin C, estensively
washed and then incubated with 1 × 105 allogenic PBMCs
(containing the responder allogenic lymphocytes) at a
15:1 PBMC/DC ratio. Lymphocytes alone and myt-
omicin-treated tumours (HT29, HT29-dx cells or HT29-
iNOS-) alone were also plated in parallel sets. Experiments
were performed in 96-wells cells culture plates in RPMI-
1640 medium supplemented with 10% FBS. To text the
extent of DNA synthesis, 1 μCi/ml [methyl-3H]-deoxythy-
midine (PerkinElmer) was added in cells culture at day 4,
and after 16 h the samples were harvested onto glass fibre
filters. [methyl-3H]-deoxythymidine incorporation was
evaluated by β-scintillation counting and expressed as
count per minute (cpm)/105 cells. The proliferation index
(PI) was calculated as cpm of PBMC incubated with the
stimulatory cells/PBMC cultured alone. When applicable,
the cpm induced by the tumour alone were subtracted to
the cpm obtained with tumour-loaded DC.
Statistical Analysis
All data in text and figures are provided as mean ± SE. The
results were analysed by a one-way analysis of variance
(ANOVA) and Tukey's test. p < 0.05 was considered signif-
icant.
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